Current standard therapy for acute coronary syndrome is dual antiplatelet therapy, combining aspirin with an inhibitor of ADP platelet receptor P2Y12, together with anticoagulants, heparin or anticoagulation pentose, and for some high-risk patients, platelet membrane glycoprotein (GP) Ⅱb/Ⅲa antagonists, if needed. Also, the secondary prevention of ischemic events requires a certain period of dual antiplatelet therapy, followed by life-long suitable dose of aspirin or clopidogrel. However, antiplatelet drug, a double-edged sword, its improved antiplatelet efficacy is offset by an increased risk of bleeding, such as stroke, severe visceral bleeding, and so on. Therefore, when selecting the anti-platelet drugs, clinicians should weigh the pros and cons and make comprehensive analysis, so as to obtain the best therapeutic effect and minimize the bleeding and other adverse reactions at the same time.